Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 5/20 | 0.48 |
| ▸ | MMP9 | P14780 | 4/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23054695 | 1.00 | CMA1 (0.49) | CMA1MMP1MMP9MMP3MEN1 | |
| SCHEMBL17360678 | 0.82 | EHMT2 (0.61) | CMA1MMP1MMP9MMP3MEN1 | |
| SCHEMBL17360672 | 0.79 | EHMT2 (0.56) | CMA1MMP1MMP9MMP3MEN1 | |
| SCHEMBL17971340 | 0.77 | EHMT2 (0.54) | CMA1MMP1MMP9MMP3MEN1 | |
| SCHEMBL17971353 | 0.77 | EHMT2 (0.54) | CMA1MEN1KMT2AGSK3AGSK3B | |
| SCHEMBL17360669 | 0.72 | MMP1 (0.53) | CMA1MMP1MMP9MMP3MEN1 | |
| SCHEMBL17360668 | 0.70 | CMA1 (0.56) | CMA1MMP1MMP9MMP3MEN1 | |
| SCHEMBL17360659 | 0.70 | CMA1 (0.56) | CMA1MMP1MMP9MMP3MEN1 | |
| SCHEMBL14813902 | 0.69 | MMP1 (0.56) | CMA1MMP1MMP9MMP3MEN1 | |
| SCHEMBL21847080 | 0.69 | KDM4E (0.51) | CMA1MMP1MMP9MMP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3650026-B1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR DERIVATIVE THEREOF, OR PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PULMONARY HYPERTENSION, CONTAINING PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VASTHERA CO LTD (KR) | 2025-10-01 | — | — | EP | disclosed |
| EP-2958926-B1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO LTD (KR) | 2023-03-08 | — | — | EP | disclosed |
| EP-3650026-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR DERIVATIVE THEREOF, OR PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PULMONARY HYPERTENSION, CONTAINING PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VASTHERA Co. Ltd. (KR) | 2020-05-13 | — | — | EP | disclosed |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | VASTHERA CO. LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | VASTHERA CO. LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| US-20190298732-A1 | PHARMACEUTICAL COMPOSITION COMPRISING EPIDITHIODIOXOPIPERAZINE COMPOUND OR DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR PREVENTING OR TREATING PULMONARY HYPERTENSION | VASTHERA CO. LTD (KR) | 2019-10-03 | — | — | US | disclosed |
| US-20180305377-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2018-10-25 | — | — | US | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO. LTD. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO. LTD. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO. LTD. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-08-04 | — | — | US | disclosed |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-08-04 | — | — | US | disclosed |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-08-04 | — | — | US | disclosed |
| EP-2958926-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | Ewha University-Industry Collaboration Foundation (KR) | 2015-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | CMA1 1986/4885MMP1 484/4885MMP9 1201/4885 |
| US-20190298732-A1 | PHARMACEUTICAL COMPOSITION COMPRISING EPIDITHIODIOXOPIPERAZINE COMPOUND OR DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR PREVENTING OR TREATING PULMONARY HYPERTENSION | IL5, NPPA, REN | CMA1 2495/4885MMP1 1853/4885MMP9 2893/4885 |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | CMA1 1986/4885MMP1 484/4885MMP9 1201/4885 |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | PRDX1, PRDX2, PRDX5 | CMA1 1986/4885MMP1 484/4885MMP9 1201/4885 |
| US-20180305377-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | CMA1 1986/4885MMP1 484/4885MMP9 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.